Objective: To probe into the efficacy of oral valganciclovir in the treatment of a case of neonatal congenital cytomegalovirus infection. Methods: A newborn with congenital cytomegalovirus infection was treated with oral administration of 16 mg/kg bid valganciclovir for 6 weeks. Body weight

head circumference

neutrophils

platelets

direct bilirubin

alanine aminotransferase and viral load were monitored; and follow-up was performed on cranial ultrasound

brainstem auditory evoked potential and head magnetic resonance imaging (MRI). Results: At the end of therapy

the newborn was negative for cytomegalovirus in urine and plasma

the hearing and developmental results were improved. Granulocytopenia that occurred during treatment were improved after treatment. Conclusions: Oral valganciclovir is effective in the treatment of congenital cytomegalovirus infection

and further research is needed to determine the optimal dose and course of treatment to achieve better efficacy and safety.